Transfer hydrogenation catalysis in cells as a new approach to anticancer drug design

Joan J. Soldevila-Barreda, Isolda Romero-Canelón, Abraha Habtemariam, Peter J. Sadler*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

146 Citations (Scopus)
99 Downloads (Pure)


Organometallic complexes are effective hydrogenation catalysts for organic reactions. For example, Noyori-type ruthenium complexes catalyse reduction of ketones by transfer of hydride from formate. Here we show that such catalytic reactions can be achieved in cancer cells, offering a new strategy for the design of safe metal-based anticancer drugs. The activity of ruthenium(II) sulfonamido ethyleneamine complexes towards human ovarian cancer cells is enhanced by up to 50 × in the presence of low non-toxic doses of formate. The extent of conversion of coenzyme NAD+ to NADH in cells is dependent on formate concentration. This novel reductive stress mechanism of cell death does not involve apoptosis or perturbation of mitochondrial membrane potentials. In contrast, iridium cyclopentadienyl catalysts cause cancer cell death by oxidative stress. Organometallic complexes therefore have an extraordinary ability to modulate the redox status of cancer cells.

Original languageEnglish
Article number6582
Number of pages9
JournalNature Communications
Publication statusPublished - 20 Mar 2015

ASJC Scopus subject areas

  • Chemistry(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Physics and Astronomy(all)


Dive into the research topics of 'Transfer hydrogenation catalysis in cells as a new approach to anticancer drug design'. Together they form a unique fingerprint.

Cite this